Remote loading of preencapsulated drugs into stealth liposomes

Cyclodextrin-based supramolecular systems for drug delivery: Recent progress and future perspective

(2013) Jianxiang Zhang et al.   ADVANCED DRUG DELIVERY REVIEWS

Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53

(2013) Mourad Sanhaji et al.   CELL CYCLE

Encapsulation of Trans-Dehydrocrotonin in Liposomes: An Enhancement of the Antitumor Activity

(2013) T. L. S. Lapenda et al.   Journal of Biomedical Nanotechnology

Novel tretinoin formulations: a drug-in-cyclodextrin-in-liposome approach

(2013) Andreia Ascenso et al.   JOURNAL OF LIPOSOME RESEARCH

Pluronic F127-modified liposome-containing tacrolimus-cyclodextrin inclusion complexes: improved solubility, cellular uptake and intestinal penetration

(2013) Quanlei Zhu et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Translating materials design to the clinic

(2013) Jeffrey A. Hubbell et al.   NATURE MATERIALS

Stimuli-responsive nanocarriers for drug delivery

(2013) Simona Mura et al.   NATURE MATERIALS

Delivery materials for siRNA therapeutics

(2013) Rosemary Kanasty et al.   NATURE MATERIALS

Enhanced Antiproliferative Activity of the New Anticancer Candidate LPSF/AC04 in Cyclodextrin Inclusion Complexes Encapsulated into Liposomes

(2012) Elisângela A. M. Mendonça et al.   AAPS PHARMSCITECH

The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo

(2012) Hiroshi Maeda et al.   ADVANCED DRUG DELIVERY REVIEWS

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

(2012) K Mross et al.   BRITISH JOURNAL OF CANCER

A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer

(2012) Peter M. Ellis et al.   Clinical Lung Cancer

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours

(2012) A. Frost et al.   Current Oncology

Native and β-cyclodextrin-enclosed curcumin: entrapment within liposomes and theirin vitrocytotoxicity in lung and colon cancer

(2012) Shafiur Rahman et al.   DRUG DELIVERY

Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53

(2012) Xiangbing Meng et al.   GYNECOLOGIC ONCOLOGY

Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions

(2012) Sweta Modi et al.   JOURNAL OF CONTROLLED RELEASE

The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study

(2012) Julie M. Vose et al.   LEUKEMIA & LYMPHOMA

Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo

(2011) Xianzhe Liu et al.   ANTI-CANCER DRUGS

Combined Gene Expression Profiling and RNAi Screening in Clear Cell Renal Cell Carcinoma Identify PLK1 and Other Therapeutic Kinase Targets

(2011) Y. Ding et al.   CANCER RESEARCH

Small Molecule Kinase Inhibitor Screen Identifies Polo-Like Kinase 1 as a Target for Neuroblastoma Tumor-Initiating Cells

(2011) Natalie Grinshtein et al.   CANCER RESEARCH

Drug delivery vehicles with improved encapsulation efficiency: taking advantage of specific drug–carrier interactions

(2011) Katarzyna Kita et al.   Expert Opinion on Drug Delivery

Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increasedin vivoactivity

(2011) Jerzy Gubernator   Expert Opinion on Drug Delivery

Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma

(2011) Santosh S. Dhule et al.   Nanomedicine-Nanotechnology Biology and Medicine

Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects

(2010) Kazuo Maruyama   ADVANCED DRUG DELIVERY REVIEWS

The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect

(2010) Jun Fang et al.   ADVANCED DRUG DELIVERY REVIEWS

Polo-Like Kinase 1 is a Therapeutic Target in High-Risk Neuroblastoma

(2010) S. Ackermann et al.   CLINICAL CANCER RESEARCH

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

(2010) R.-D. Hofheinz et al.   CLINICAL CANCER RESEARCH

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

(2010) E. B. Haura et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

(2010) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma

(2010) Helen J. Stewart et al.   EXPERIMENTAL HEMATOLOGY

Recent developments in lipid-based pharmaceutical nanocarriers

(2010) Tiziana Musacchio   Frontiers in Bioscience-Landmark

Cyclodextrins for drug delivery

(2010) A.L. Laza-Knoerr et al.   JOURNAL OF DRUG TARGETING

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

(2010) Christophe Frémin et al.   Journal of Hematology & Oncology

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

(2010) Martin Sebastian et al.   Journal of Thoracic Oncology

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

(2010) Mark E. Davis et al.   NATURE

Clinical Developments in Nanotechnology for Cancer Therapy

(2010) Jeremy D. Heidel et al.   PHARMACEUTICAL RESEARCH

Identification of Polo-like Kinase 1 as a Potential Therapeutic Target in Anaplastic Thyroid Carcinoma

(2009) T. C. Nappi et al.   CANCER RESEARCH

Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties

(2009) Daniel Zucker et al.   JOURNAL OF CONTROLLED RELEASE

PD0325901, a Mitogen-Activated Protein Kinase Kinase Inhibitor, Produces Ocular Toxicity in a Rabbit Animal Model of Retinal Vein Occlusion

(2009) Wenhu Huang et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

(2009) S. Sur et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles

(2009) C. H. J. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inclusion complexes of tadalafil with natural and chemically modified β-cyclodextrins. I: Preparation and in-vitro evaluation

(2008) Shaimaa M. Badr-Eldin et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

(2008) Klaus Mross et al.   JOURNAL OF CLINICAL ONCOLOGY

Imaging characteristics of zinc sulfide shell, cadmium telluride core quantum dots

(2008) Hamid Daneshvar et al.   Nanomedicine

Cyclodextrins

(2008) Valentino J. Stella et al.   TOXICOLOGIC PATHOLOGY